IRIS
GENOVA, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.509
AS - Asia 2.564
NA - Nord America 2.353
SA - Sud America 223
AF - Africa 45
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 17.701
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 12.097
US - Stati Uniti d'America 2.197
SG - Singapore 852
CN - Cina 616
BD - Bangladesh 452
VN - Vietnam 356
FR - Francia 150
BR - Brasile 133
HK - Hong Kong 98
CA - Canada 63
FI - Finlandia 60
DE - Germania 47
AR - Argentina 39
IN - India 34
NL - Olanda 31
JP - Giappone 30
GB - Regno Unito 29
ID - Indonesia 22
JM - Giamaica 19
MX - Messico 17
ZA - Sudafrica 17
MY - Malesia 15
RU - Federazione Russa 12
CH - Svizzera 11
EC - Ecuador 11
TR - Turchia 11
CR - Costa Rica 10
HN - Honduras 10
PY - Paraguay 10
UZ - Uzbekistan 10
IQ - Iraq 9
PH - Filippine 9
UA - Ucraina 9
CO - Colombia 8
GT - Guatemala 8
PL - Polonia 8
VE - Venezuela 8
ES - Italia 7
DZ - Algeria 6
GR - Grecia 6
RO - Romania 6
SA - Arabia Saudita 6
SV - El Salvador 6
UY - Uruguay 6
AU - Australia 5
IE - Irlanda 5
NP - Nepal 5
RS - Serbia 5
NI - Nicaragua 4
PK - Pakistan 4
PR - Porto Rico 4
SE - Svezia 4
TT - Trinidad e Tobago 4
AT - Austria 3
CL - Cile 3
EG - Egitto 3
ET - Etiopia 3
HR - Croazia 3
KE - Kenya 3
KW - Kuwait 3
LB - Libano 3
MA - Marocco 3
OM - Oman 3
PE - Perù 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BE - Belgio 2
BS - Bahamas 2
GA - Gabon 2
GE - Georgia 2
JO - Giordania 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
SI - Slovenia 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
AL - Albania 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GP - Guadalupe 1
GY - Guiana 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
LC - Santa Lucia 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
Totale 17.686
Salva come PNG Salva come JPEG
Città #
Genoa 5.241
Genova 3.882
Vado Ligure 1.284
Rapallo 1.273
San Jose 418
Singapore 393
Ashburn 338
Council Bluffs 145
Lauterbourg 136
Ho Chi Minh City 107
New York 97
Hong Kong 93
Beijing 91
St Louis 82
Hanoi 80
Helsinki 54
Santa Clara 45
Los Angeles 44
Milan 42
Frankfurt am Main 38
Rome 35
Buffalo 33
Boardman 26
Bordighera 26
Chicago 25
Tokyo 25
Naples 22
Dallas 17
Houston 16
Amsterdam 15
Atlanta 15
Philadelphia 15
Tianjin 15
Da Nang 14
Orem 14
São Paulo 14
Haiphong 12
Toronto 12
Biên Hòa 11
Phoenix 11
City of London 10
Mexico City 10
Montreal 10
New Delhi 10
Guangzhou 9
Jamaica Plain 9
Bologna 8
Johannesburg 8
Kingston 8
Turin 8
Brooklyn 7
Catania 7
Charlotte 7
Guatemala City 7
Hải Dương 7
Newark 7
Piscataway 7
Queens 7
Rio de Janeiro 7
San José 7
Seattle 7
Tashkent 7
Warsaw 7
Billings 6
Jakarta 6
Kuala Lumpur 6
Lappeenranta 6
Miami 6
Padua 6
Palermo 6
Phủ Lý 6
Shenzhen 6
Washington 6
Asunción 5
Bari 5
Can Tho 5
Chennai 5
Dublin 5
Guayaquil 5
Jersey City 5
Kansas City 5
Las Vegas 5
North Charleston 5
San Salvador 5
Shanghai 5
Zurich 5
Baghdad 4
Birmingham 4
Buenos Aires 4
Cagliari 4
Cardiff 4
Cincinnati 4
Cleveland 4
Dhaka 4
Florence 4
Istanbul 4
Jacksonville 4
London 4
Madrid 4
Managua 4
Totale 14.618
Salva come PNG Salva come JPEG
Nome #
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. 282
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 202
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 201
Efficacy of motesanib diphosphate in non-small-cell lung cancer. 188
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. 181
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 181
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 180
CORRELATION BETWEEN B7-H4 EXPRESSION AND SURVIVAL OF NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH NIVOLUMAB 180
Belagenpumatucel-L for the treatment of non-small cell lung cancer 178
Harnessing NK Cells for Cancer Treatment 176
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors 172
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 171
Next Generation Sequencing In Non-Small Cell Lung Cancer: New Avenues Toward The Personalized Medicine. 171
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 170
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients 169
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients 164
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 163
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 162
Radiomic detection of EGFR mutations in NSCLC 161
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab 156
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells 155
Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: a pooled analysis of case reports 152
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. 152
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab 152
Oral vinorelbine in the treatment of non-small-cell lung cancer. 150
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives 149
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 149
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 148
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 148
Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer 147
Afatinib for the treatment of advanced non-small-cell lung cancer. 146
Liquid biopsy in non-small cell lung cancer: Highlights and challenges 143
Novel emerging molecular targets in non-small cell lung cancer 143
Expression of ribonucleotide reductase subunit-2 and thymidylate synthase correlates with poor prognosis in patients with resected stages I-III non-small cell lung cancer 142
Next-generation sequencing workflow for NSCLC critical samples using a targeted sequencing approach by ion torrent PGM™ platform 142
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors 142
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 141
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer 141
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. 140
Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients 139
Immune Checkpoint Inhibitors-Related Myastenia Gravis, Myocarditis and Myositis: A Systematic Review of Cases 138
Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study 138
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 137
Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitors 136
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 136
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients 136
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 135
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 135
A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry 135
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 133
Afatinib for the treatment of non-small cell lung cancer 133
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 133
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update 132
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 131
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade 131
Platelets and their derived extracellular vesicles: The new generation of markers in non-small cell lung cancer management 130
An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis 130
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors 128
Potential application of cryobiopsy for histo-molecular characterization of mediastinal lymph nodes in patients with thoracic malignancies: a case presentation series and implications for future developments 128
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives 126
Approaches to Fertility Preservation for Young Women With Breast Cancer 126
Current practices in oncofertility counseling: updated evidence on fertility preservation and post-treatment pregnancies in young women affected by early breast cancer 125
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 124
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 124
Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms 123
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation 122
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 121
Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics 117
CD34+DNAM-1brightCXCR4+ haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells 117
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 116
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 116
Role of microRNAs in malignant mesothelioma. 115
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 115
Primary endobronchial melanoma: a case report and clinical management indications 113
Palliative treatment of life-threatening hemoptysis with silicone stent insertion in advanced lung cancer 112
ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium 110
Radiomic-based diagnostics in oncology: challenges toward clinical practice 110
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review 109
Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (Nsclc): A real world experience 108
Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer 107
Pemetrexed for the treatment of non-small cell lung cancer. 107
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 107
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy 107
Rapid On-Site Evaluation Performed by an Interventional Pulmonologist: A Single-Center Experience 106
Recent advances in squamous non-small cell lung cancer: Evidence beyond predictive biomarkers 106
Antibody–drug conjugates for lung cancer in the era of personalized oncology 106
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 105
Hematopoietic growth factors in lung cancer 104
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 103
Vinflunine for the treatment of non-small cell lung cancer 103
Call for ensuring cancer care continuity during COVID-19 pandemic 101
Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma 100
Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Focus on challenging populations 100
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer 99
Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples 98
Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression 98
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 97
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines 97
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 96
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 96
Totale 13.556
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.668
article - articoli 69.301
book - libri 0
conference - conferenze 469
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 471
Totale 140.909
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.182 88 27 31 76 63 86 30 253 140 120 75 193
2022/20231.509 136 104 26 141 262 242 17 138 227 27 172 17
2023/20241.016 39 107 34 137 76 151 80 58 46 71 44 173
2024/20253.429 115 198 93 274 431 353 312 602 155 217 309 370
2025/20267.563 743 307 563 645 807 503 958 341 644 756 636 660
2026/2027537 537 0 0 0 0 0 0 0 0 0 0 0
Totale 18.224